

ASX Announcement

7 October 2020

Canopy Growth founder Bruce Linton appointed as Strategic Advisor

- **Mr Linton led Canopy Growth Corporation from founding the start up to the first cannabis producing company listed on the NYSE – peak market capitalisation during his six-year tenure was US\$15 Billion**
- **As Chairman & CEO of Canopy Growth he secured market support for 16 rounds of financing, totalling more than US\$5 Billion in capital raises and oversaw upwards of US\$3 Billion in 30 M&A transactions**
- **Bruce has extensive sector experience and holds multiple positions with international companies – he has also worked with large financial institutions including the World Bank**
- **Bruce's expertise, deep industry network and experience will further shape and expedite global expansion**

Creso Pharma Limited (ASX:CPH) (the **Company**) is pleased to advise that its subsidiary Creso Pharma Switzerland GMBH (**Creso Pharma**) has appointed Canopy Growth Corporation (TSX:WEED, NYSWE:CGC) ("Canopy Growth") founder and ex-CEO Mr Bruce Linton as a strategic advisor.

Mr Linton is one of the world's leading cannabis executives and an accomplished entrepreneur. He has extensive sector experience as a founder, CEO, Board member and adviser to a number of global cannabis companies.

Bruce's major achievements include his role as founder, Chairman and ex-CEO of Canopy Growth Corporation, during which time Canopy Growth Corporation's market capitalisation reached US\$15 Billion (and was approximately US\$11B upon his resignation in 2019). During his time with the Canopy Growth, he secured market support for over 16 rounds of financing of over US\$5 Billion in public capital markets and private placements and more than 30 M&A activities. He led Canopy Growth through the start-up phase to becoming the first cannabis producing company to list on the New York Stock Exchange (NYSE). Canopy Growth has remained the largest listed cannabis companies on the NYSE since its IPO.

Following his departure from Canopy Growth Corporation in 2019, Bruce led direct investments into the sector and held both management positions and strategic advisory roles.

He currently sits as Executive Chair of Gage Cannabis Co.. He has also diversified into the psychedelic drug space, as a director of psychedelic inspired medicine company Mind Medicine Inc.

He is also the Co-Chairman and former CEO of technology company Martello Technologies Group Inc. (CVE:MTLO) and Co-Founder of Ruckify Software. He has also worked extensively with international institutions such as the World Bank.

Mr Linton was attracted to Creso Pharma for its unique IP, established global distribution footprint and robust product pipeline targeting distinct categories. He believes this puts Creso Pharma in the optimal position to excel internationally and continue to develop innovative products to complement its existing portfolio.

As strategic advisor over a 24-month term, Mr Linton will leverage his connections, expertise and influence in the industry to consult and work closely with Creso Pharma's Board to shape its long-term strategy and various near term corporate and operational initiatives.

In consideration for Mr Linton's services and to align Mr Linton's interests with those of shareholders, the Company will, subject to shareholder approval, issue 30,000,000 Options to Mr Linton (or his nominee), each with an exercise price of \$0.039 and an expiry date of 5 years from the date of issue.

Management commentary:

Creso Director Miri Halperin Wernli said, "Bruce brings a wealth of invaluable knowledge and a deep network of cannabis industry contacts to Creso Pharma and we anticipate that his appointment will greatly assist us in achieving our near term operational milestones and longer term goals.

"We continue to target international distribution agreements in a number of new markets and progress product development initiatives that will unlock considerable shareholder value. We look forward to providing further updates in the near term."

-Ends-

Authority and Contact Details

This announcement has been authorised for release by the Company Board

For further information, please contact:

Investor Enquiries

EverBlu Capital

E: info@everblucapital.com

P: +61 2 8249 0000

**About Creso Pharma**

Creso Pharma Limited (ASX:CPH) brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health. The Company uses GMP development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids. To learn more please visit: www.cresopharma.com

Forward Looking statements

This announcement contains forward-looking statements with respect to the Company and its respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations.

The actual results and performance of the Company could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to the Company and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and the Company has no obligation to up-date such statements, except to the extent required by applicable laws.